Predictive factors of recurrent angina after acute coronary syndrome: The global registry acute coronary events from China (Sino-GRACE)

Chinese Medical Journal

Volumn 121, Issue 1, 2008, Pages 12-16

  Zhao, Fu Hai ^a   Chen, Yun Dai ^a   Song, Xian Tao ^a   Pan, Wei Qi ^a   Jin, Ze Ning ^a   Yuan, Fei ^a   Li, Yong Bin ^a   Ren, Fang ^a   Lü, Shu Zheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Predictive factors; Recurrent angina pectoris

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ANGINA PECTORIS; ARTICLE; BLEEDING; CHINA; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HEART REINFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RECURRENT DISEASE; REGISTER; REGRESSION ANALYSIS; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

EID: 38349140961     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200801010-00003     Document Type: Article

References (24)

1. Fuchs I, Frossard M, Spiel A, Riedmüller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 4: 2547-2552.
2. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 874-881.
3. Latchamsetty R, Fang J, Kline-Rogers E, Mukherjee D, Otten RF, LaBounty TM, et al. Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol 2007; 99: 939-942.
4. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190-199.
5. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291: 2727-2733.
6. Song XT, Chen YD, Pan WQ, Lü SZ; For the CRACE investigators. Gender based differences in patients with acute coronary syndrome: findings from Chinese Registry of Acute Coronary Events (CRACE). Chin Med J 2007; 120: 1063-1607.
7. Glaser R, Selzer F, Jacobs AK, Laskey WK, Kelsey SF, Holper EM, et al. Effect of gender on prognosis following percutaneous coronary intervention for stable angina pectoris and acute coronary syndromes. Am J Cardiol 2006; 98: 1446-1450.
8. Bounhoure JP, Farah B, Fajadet J, Marco J. Prognosis after acute coronary syndrome. Lack of difference according to the sex. Bull Acad Natl Med 2004; 188: 383-397.
9. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study. Circulation 2004; 110: 386-391.
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
11. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278: 2093-2098.
12. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ; PCAT Collaborators. Percutaneous transluminal coronary angioplasty. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month followup and analysis of individual patient data from randomized trials. Am Heart J 2003; 145: 47-57.
13. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26: 1643-1650.
14. Mehta SR, Eikelboom JW, Demers C, Maggioni AP, Commerford PJ, Yusuf S. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Can J Physiol Pharmacol 2005; 83: 98-103.
15. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez-Sendon J, Sharpe N, Investigators CES. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004; 109: 201-206.
16. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807-2816.
17. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101: 2103-2109.
18. Jackson JD, Muhlestein JB, Bunch TJ, Bair TL, Horne BD, Madsen TE, et al. Intermountain Heart Collaborative Study G. Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J 2003; 145: 875-881.
19. Ricci R, Coletta C, Ceci V, Pajes G, Putini RL, Salustri A, et al. Effect of early treatment with captopril and metoprolol singly and together on postinfarction left ventricular remodeling. Am Heart J 2001; 142: E5.
20. Sia YT, Parker TG, Tsoporis JN, Liu P, Adam A, Rouleau JL. Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharmacol 2002; 39: 73-87.
21. Galcerá-Tomás J, Castillo-Soria FJ, Villegas-García MM, Florenciano-Sánchez R, Sánchez-Villanueva JG, de La Rosa JA, et al. Effects of early use of atenolol or captopril on infarct size and ventricular volume: A double-blind comparison in patients with anterior acute myocardial infarction. Circulation 2001, 103: 813-819.
22. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation 2000; 102: 166-172.
23. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-437.
24. Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, et al. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2007; 99: 202-207.